Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;7(1):52-67.
doi: 10.1177/2040622315612745.

Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management

Stacey Ackerman  1 , Lisa M Smith  2 , Paulo J Gomes  2
Affiliations
Review

Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management

Stacey Ackerman et al. Ther Adv Chronic Dis. 2016 Jan.

Abstract

Allergic conjunctivitis is one of the most common allergic conditions worldwide. Its incidence is increasing due to changing climate, pollution, increased pollen loads, and the subject's heightened immunological sensitivity in response to these environmental changes. The pathophysiology predominantly involves immunoglobulin E-related mast-cell activation, with release of histamine and other mediators contributing to the propagation of the response by calling in other immune cells and further inflammation. This article presents the evolution of ocular allergy treatments, from vasoconstrictors, to antihistamines and mast-cell stabilizers, to the dual-acting agents, as well as corticosteroid and immunomodulatory options. Future targets for allergy treatment are also discussed.

Keywords: CAC; IgE; alcaftadine; allergic conjunctivitis; antihistamines; histamine; mast cell; ocular itching; olopatadine.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interest: Dr. Ackerman has received financial consideration in connection with certain ocular allergy therapeutics. L Smith and P. Gomes are employees of Ora, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

    1. AAO. (2011) American Academy of Ophthalmology Cornea/External Disease Panel: Conjunctivitis, Limited Revision. San Francisco, CA: American Academy of Ophthalmology.
    1. Abelson M. (2004) A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother 5: 1979–1994. - PubMed
    1. Abelson M., Chambers W., Smith L. (1990a) Conjunctival allergen challenge: a clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 108: 84–88. - PubMed
    1. Abelson M., Gomes P., Crampton H., Schiffman R., Bradford R., Whitcup S. (2004a) Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 26: 35–47. - PubMed
    1. Abelson M., Gomes P., Vogelson C., Pasquine T., Gross R., Turner F., et al. (2004b) Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin Ther 26: 1237–1248. - PubMed